Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:GILD News 6 December 2025 - 28 January 2026

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Gilead Sciences shares rose 2.3% to $140.97 Tuesday, hitting a 52-week high after Medicare named its HIV drug Biktarvy for price negotiations starting in 2028. Trading volume topped 10.5 million shares. CEO Daniel O’Day sold 115,640 shares last week under a pre-set plan. Gilead will report fourth-quarter and full-year results after markets close on Feb. 10.
28 January 2026
···
Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead Sciences shares rose 1.8% to $140.24 Tuesday afternoon, hitting a 12-month high of $141.69 earlier in the session. Citi, Truist, and BMO raised price targets following upbeat analyst notes and strong momentum for the company’s HIV prevention drug Yeztugo. Investors await early February results and Gilead’s earnings, expected around Feb. 10.
27 January 2026
···
Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead Sciences shares closed at a 52-week high of $137.78 on Monday, up 1.36% for a fourth straight gain. CEO Daniel O’Day sold $15.6 million in stock under a pre-set plan, according to an SEC filing. BMO and UBS raised their price targets, citing momentum in HIV drugs and new coverage for Yeztugo. Trading volume exceeded normal levels as the stock outperformed major pharma peers.
27 January 2026
··
Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead Sciences shares rose 0.9% to $137.21 midday Monday after BMO Capital Markets raised its price target to $150, citing expanded insurance coverage for Yeztugo, Gilead’s new HIV prevention shot. CVS confirmed coverage starting Jan. 1, pushing overall insurer coverage above 80%. Gilead says it has already met its 2025 Yeztugo sales target of $150 million. Investors await Gilead’s earnings report, expected Feb. 10.
26 January 2026
·
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead Sciences shares rose 3.65% to $135.93 after Phase 3 trial results showed Trodelvy plus Keytruda cut the risk of breast cancer progression or death by 35% versus Keytruda and chemotherapy. The company has submitted regulatory filings in the U.S. and Europe. CEO Daniel O’Day plans to sell up to $15.6 million in shares. Investors await Gilead’s earnings report on Feb. 10.
24 January 2026
·
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead Sciences shares slipped 0.2% to $124.68 Tuesday, outperforming a broader market drop. Bernstein reiterated its Outperform rating and $135 target, citing Yeztugo as a key 2026 driver. Florida announced steep cuts to its AIDS Drug Assistance Program, drawing criticism from advocates and raising concerns over HIV drug access.
20 January 2026
··
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

NEW YORK, December 29, 2025, 22:17 ET — Market closed Gilead Sciences (GILD.O) shares were last up 0.15% at $124.91 on Monday, as investors weighed an analyst note that argued new Medicaid drug-pricing rules would have a limited financial impact on the company’s HIV franchise. Investing.com The call matters now because drugmakers and investors are still parsing a Trump administration pricing push that targets Medicaid and aims to bring U.S. medicine prices closer to those in other wealthy countries. Reuters For Gilead, the focus has been on whether “most-favored-nation” pricing — a policy that effectively ties prices to lower international
30 December 2025
·
Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025

Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025

Gilead Sciences, Inc. (NASDAQ: GILD) ended the Dec. 23, 2025 session modestly higher and was little changed after the closing bell—a calm tape that masks a busy fundamental backdrop heading into a holiday-shortened Christmas Eve trading day. As investors look toward Wednesday’s open (Dec. 24, 2025), the “what matters” list for GILD is less about tonight’s after-hours tick and more about the headlines that could shape sentiment into year-end: Gilead’s move to expand its antiviral pipeline with a new herpes program, the company’s upcoming J.P. Morgan Healthcare Conference appearance, and the still-fresh U.S. drug-pricing/tariff-relief agreements that are reshaping how big
24 December 2025
·
Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences, Inc. (NASDAQ: GILD) ended the regular session on Monday, December 22, 2025 essentially flat, and the stock showed only a modest change in post-market trading—yet the news flow behind the scenes was anything but quiet. After the closing bell, investors were digesting a fresh antiviral pipeline update tied to a new genital herpes program, plus a newly confirmed appearance at January’s heavyweight healthcare investor conference—both of which can shape sentiment as markets reopen on Tuesday, December 23, 2025. StockAnalysis+2Gilead+2 GILD after-hours check: where the stock stands tonight Here’s the key price action from Monday’s session and the after-hours
23 December 2025
·
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences, Inc. (NASDAQ: GILD) opened the holiday-shortened week with a mix of pipeline expansion and policy-driven uncertainty—two themes that can quickly move large-cap biopharma stocks even when overall market volume is lighter than usual. On Monday, December 22, 2025, Gilead announced it has exercised its option to license Assembly Biosciences’ investigational herpes simplex virus (HSV) programs—a move that strengthens Gilead’s long-term antiviral pipeline beyond HIV. The development lands just days after Gilead joined other major drugmakers in a Trump administration “most-favored-nation” drug-pricing agreement tied to tariff relief and direct-to-consumer drug access via TrumpRx.gov. Gilead+2Gilead+2 As of the latest available
22 December 2025
·
Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Ahead of the U.S. market open on Monday, December 22, 2025 (the next trading session after Friday’s close), Gilead Sciences, Inc. (NASDAQ: GILD) is in focus for two reasons that matter to both short-term traders and long-term investors: a new U.S. government drug-pricing agreement that could reshape near-term sentiment across big pharma, and fresh late-stage HIV pipeline success that reinforces Gilead’s core franchise heading into 2026. Gilead+1 Below is a market-ready briefing—current catalysts, what analysts are watching, key numbers, and the biggest risks—written for readers looking to understand what could move GILD stock as the bell approaches. GILD stock snapshot
22 December 2025
·
Gilead Sciences (GILD) Stock Week-Ahead Outlook: Pricing Deal Shockwave, HIV Pipeline Momentum, and Key Catalysts for Dec 22–26, 2025

Gilead Sciences (GILD) Stock Week-Ahead Outlook: Pricing Deal Shockwave, HIV Pipeline Momentum, and Key Catalysts for Dec 22–26, 2025

December 21, 2025 — Gilead Sciences, Inc. (NASDAQ: GILD) heads into a holiday-shortened trading week with an unusually dense mix of policy headlines and pipeline momentum—two forces that can quickly reprice a large-cap biopharma stock even when overall market volume is thin. Gilead ended the most recent session around $124.29, a level investors will treat as the near-term “line in the sand” as markets navigate Christmas week liquidity, fresh U.S. drug-pricing agreements, and renewed optimism around Gilead’s HIV franchise. Below is a week-ahead, publication-ready briefing on the latest Gilead news, forecasts, and market analysis as of Dec. 21, 2025, and
21 December 2025
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
·········
Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Updated: December 20, 2025 Gilead Sciences, Inc. (NASDAQ: GILD) heads into the weekend with fresh policy headlines, a high-profile pricing agreement tied to the Trump administration’s TrumpRx initiative, and renewed attention on the company’s next-generation HIV portfolio. The combination has kept Gilead stock near the top of its recent trading range—while also reopening the debate investors have wrestled with all year: how much upside can the pipeline deliver, and how much risk does U.S. pricing policy introduce? Below is a comprehensive look at what’s driving Gilead shares as of 20.12.2025, what analysts are forecasting next, and the key catalysts (and
20 December 2025
··
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3 Below is a comprehensive roundup of the most market-moving healthcare news, plus the latest forecasts and sector analysis shaping how investors are positioning across pharma, biotech, managed care, medtech, and healthcare services into 2026. 1) Drug pricing is
20 December 2025
········
Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences, Inc. (NASDAQ: GILD) ended Friday, December 19, 2025, with a sharp, high-volume move that kept traders focused into the after-hours session. The headline drivers were a new U.S. government pricing agreement tied to TrumpRx.gov and tariff relief, plus a fresh U.K. regulatory approval for lenacapavir—two catalysts that hit the tape on the same day and helped explain why Gilead was among the stronger large-cap pharma names into the close. Gilead stock price recap after the bell (Dec. 19 close + after-hours) Gilead’s regular session finished firmly higher, and the after-hours tape stayed constructive but calm. One notable detail:
20 December 2025
··
Gilead Sciences (GILD) Stock Today: Price, Fresh News and Analyst Outlook on December 8, 2025

Gilead Sciences (GILD) Stock Today: Price, Fresh News and Analyst Outlook on December 8, 2025

As of Monday, December 8, 2025, Gilead Sciences, Inc. (NASDAQ: GILD) sits near the upper end of its 52‑week range, supported by strong HIV franchises, new long‑acting prevention drugs, high‑profile cancer data at ASH 2025 and a steady dividend. At the same time, investors are weighing slowing COVID‑19 sales, competitive oncology pressures and policy risk. Below is a structured look at today’s price action, the latest news flow dated December 8, 2025, analyst forecasts and the medium‑term investment narrative around Gilead Sciences stock. Gilead Sciences (GILD) stock price on December 8, 2025 Gilead shares are trading around $121 per share
8 December 2025
Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (NASDAQ: GILD) heads into Monday’s session riding an event‑packed weekend: new cancer data at the ASH 2025 hematology meeting, fresh institutional‑ownership filings, and another round of valuation work from analysts and quant platforms. Here’s what investors should know about Gilead Sciences stock before the U.S. market opens on Monday, December 8, 2025. 1. Price action: defensive biotech near the top of its range As of the close on Friday, December 5, Gilead Sciences stock finished at $121.22, about 1.14% lower on the day; after‑hours trading nudged it slightly higher to ~$121.34. TechStock² At that level: Several recent analyses
8 December 2025
··
Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences stock (NASDAQ: GILD) is trading near the upper end of its 52‑week range as of early December 2025, supported by stronger guidance, big HIV and liver franchises, and a mixed but important year for its oncology pipeline. At the same time, new deals in cell therapy and targeted protein degradation show management leaning into long‑term cancer bets, even at the cost of a bit of near‑term EPS. Here’s a detailed look at the latest price action, earnings, drug news, analyst forecasts and key risks that matter for GILD into 2026. Gilead Sciences stock price and recent trading As
6 December 2025
···
1 2

Stock Market Today

Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

7 February 2026
China’s central bank raised gold reserves for a 15th month in January, reaching 74.19 million ounces worth $369.58 billion. Gold prices swung sharply, hitting a record near $5,600 before dropping to $4,403.24. CME Group hiked COMEX gold futures margins to 9% after recent volatility. U.S. jobs and inflation data are due next week after a delay.
Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company forecast 2026 capital spending would jump to $200 billion, up more than 50% from 2025. The drop came as the Dow closed above 50,000 for the first time. Amazon reported fourth-quarter net sales up 14% to $213.4 billion and operating income at $25 billion. Trading in Amazon was volatile, with 179 million shares changing hands.
Go toTop